BTIG Maintains Vaxcyte Buy Rating After Successful VAX-31 Trial

BTIG has reiterated its Buy rating and $89.00 price target for Vaxcyte (NASDAQ:PCVX) after the company released Phase 3 data for its VAX-31 vaccine candidate. The OPUS-1 trial results exceeded management expectations and represent a milestone for the firm's clinical pipeline.

"The data from the OPUS-1 trial supports the potential for VAX-31 to become a best-in-class pneumococcal conjugate vaccine," noted analysts in a recent BTIG report.

Clinical Performance of VAX-31

The VAX-31 candidate met all 32 prespecified co-primary endpoints in the study. When compared to the established PCV20 and PCV21 vaccines, VAX-31 demonstrated non-inferiority using a 0.50 LBCI (lower bound of the confidence interval) threshold.

When evaluated against a more stringent 0.667 LBCI threshold, the vaccine met the target in all 20 comparisons against PCV20 and 17 of 19 comparisons against PCV21. Regulators use these metrics to determine whether a new vaccine provides a comparable immune response to existing standard-of-care options.

Market Outlook and Analyst Revisions

BTIG maintained its $89.00 price target, but other financial institutions have adjusted their outlooks based on this clinical progress. BofA Securities recently updated its price target for Vaxcyte to $130.00. This revision follows a recalibration of the company's commercial timeline, as the firm now projects a 2029 launch year for VAX-31.

For investors and stakeholders, the successful trial results represent a reduction in clinical risk for Vaxcyte’s lead program. The company is now positioned to advance its regulatory strategy, although the path to market remains subject to final phase completion and subsequent FDA review processes.